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Abstract
Background. To investigate the correlation of reproductive tract infections (RTI) and endogenous vaginal flora at first
antenatal consultation with placental histological inflammation. Methods. In a follow-up study, 154 low risk women with no
miscarriage risk factors were examined for the presence of Neisseria gonorrhoeae, Trichomonas vaginalis, Chlamydia
trachomatis, Ureaplasma urealyticum, Mycoplasma hominis, Gardnerella vaginalis, Streptococcus agalactiae (GBS), Staphylococcus
aureus, Enterococcus faecalis (GDS) and bacterial vaginosis (BV). At delivery, outcome data were collected and the histology
of the placenta was studied. Results. Some 85 (56.3%) of all pregnant women had RTI or endogenous vaginal flora.
Placental histological inflammation correlated with genital tract colonisation with G. vaginalis (p0.013), BV (p0.031),
S. aureus (p0.04) and aerobic vaginitis (p0.017). BV and BV-related G. vaginalis correlated with the presence of parietal
and placental chorioamnionitis in 53.8 and 43.5% of cases. Genital tract colonisation with GDS and other aerobic flora in
combination with inflammatory vaginitis correlated with the presence of funisitis in 33.3 and 40.0% of cases. Mycoplasmas
increased the risk for intrauterine infection only when present in combination with other RTIs (p0.023). Conclusion.
Histological placental inflammation is associated with both BV and genital tract colonisation with aerobic bacteria, while
funisitis is associated with colonisation of aerobic bacteria at first prenatal visit before the 17th gestational week.
Key words: Reproductive tract infections, endogenous vaginal flora, aerobic vaginitis, bacterial vaginosis, chorioamnionitis,
placenta
Abbreviations: AV: aerobic vaginitis, BV: bacterial vaginosis, CA: chorioamnionitis, GBS: Streptococcus agalactiae,
GDS: Enterococcus faecalis, IL-1: interleukin 1, RTI: reproductive tract infections, STI: sexually transmitted infections,
PROM: premature rupture of membranes, PPROM: preterm premature rupture of membranes
Introduction
Placental histological inflammation is one of the
most frequent findings in placental histology, espe-
cially if it is performed in cases of preterm birth prior
to 30 weeks’ gestation. Clinical diagnosis of intrau-
terine infection is chorioamnionitis (CA). Even
though in most situations CA is a subclinical
condition and can be diagnosed only by histological
examination of placenta (1), placental inflammation
is an important type of pathological process, leading
to fetal morbidity and mortality caused by micro-
organisms or caused by host immune response to
non-replicating antigens (2). The microorganisms
found in fetal membranes in cases of CA are the
same as those found in the lower genital tract of
pregnant women.
About 4% of infant morbidity in Latvia is due to
perinatal infections, and the incidence is still high
(3). Perinatal infection rate was 18.5 per 1,000 live
mature newborns in 2004, but in preterm newborns
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it was as high as 62.9 per 1,000 babies. In 2005, the
respective figures were 16.8 and 42.1 per 1,000 (3).
The aim of this study was to investigate the
presence of reproductive tract infections (RTIs)
(according to the WHO classification of RTIs
including sexually transmitted infections (STIs)
and overgrowth of endogenous vaginal flora in cases
of bacterial vaginosis (BV) or aerobic vaginitis (AV))
and endogenous vaginal flora (4) and their associa-
tion with placental histological inflammation. Preg-
nancy and delivery outcome data in relation to
inflammatory changes in the placenta were studied.
Materials and methods
A prospective study on the incidence of RTI and
endogenous vaginal microbial colonisation and their
influence on pregnancy outcome in Latvia was
conducted from 1997 to 2002. In total, there were
386 pregnant women included in the study during
their first antenatal visit in one of the 5 outpatient
clinics in Riga. Patients were consecutively included
if they attended the antenatal care clinic on one
particular day of the week, depending on the
availability of organised transportation. No woman
had undergone previous recurrent miscarriages or
preterm deliveries. Histological examination of pla-
centas was part of the study protocol. Placentas for
investigation were obtained in 154 cases  from all
study patients who delivered in Riga Maternity
hospital in 19982002. The mean gestational age
at the first antenatal visit varied from 6 to 12 weeks
in 146 cases, and from 1317 weeks in 8 cases. The
research protocol was reviewed and approved by the
Ethics Committee of the Riga Stradins University.
Before entry into the study, each patient signed an
informed consent and completed a specially de-
signed and approved study questionnaire.
Women were tested for BV, Neisseria gonorrhoeae
(N. gonorrhoeae), Trichomonas vaginalis (T. vagina-
lis), as included in the routine antenatal screening
program, and additionally for Chlamydia trachomatis
(C. trachomatis), Ureaplasma urealyticum (U. urealy-
ticum), Mycoplasma hominis (M. hominis), Gardner-
ella vaginalis (G. vaginalis), Streptococcus agalactiae
(GBS), Staphylococcus aureus (S. aureus) and Enter-
ococcus faecalis (GDS). The samples were obtained
from the upper part of the vagina and/or cervix. The
results were unknown to the attending gynecologist
and pregnant women received treatment only in case
of symptomatic BV, presence of N. gonorrhoeae or
T. vaginalis as foreseen in the latvian antenatal
screening program.
Aerobes were cultivated on Columbia agar with 5%
sheep blood. For identification of S. aureus, Mannitol
salt/Chapman’s medium, the catalase test and the
Slidex Staph-Kit were used. GBS and GDS were
identified by Slidex Strepto-Kit method and Bio
Merieux media. Mycoplasma Lyo was used for the
cultivation of M. hominis and U. urealyticum. For
examination of G. vaginalis, T. vaginalis and
N. gonorrhoeae microscopy method was used with
confirmation by DNA hybridisation test for
N. gonorrhoeae (5). Vaginal fluid collected with a
spatula from the posterior fornix was investigated
with methylene blue dye and Gram’s method. C.
trachomatis was examined by a DNA hybridisation
test.
For diagnosis of BV, Amsel’s criteria were used
(6). For diagnosis of AV, the following criteria were
used: positive culture for aerobic flora, patient’s
complaint of the presence of abnormal yellow
discharge, clinical signs of inflammation in vagina
or exocervix, and the presence of leucocytes10 per
high power field (7).
Placental morphology was studied using conven-
tional histological methods. Infiltration of any part of
placenta with poly-morpho-nuclear leucocytes was
recognised as placental histological inflammation.
Results were analysed using software of statistical
analysis SPSS (SPSS Inc., Chicago, IL, USA). Chi-
square and Fishers exact test were used and a
significance level of 0.05 was required for all tests.
Results
Due to its hematogenous origin, mostly caused by
viral infection, three cases of isolated villitis in
placental histology were excluded from the final
analysis. As expected, RTI was not present in these
cases.
In 46/151 (30.5%) women, placental histological
inflammation was detected. The screening data at
first prenatal visit of these 46 patients (study group)
were compared to those of the remaining 105
patients without histological signs of inflammation
in the placenta (control group).
In patients with histologically proven signs of
placental inflammation, the preterm delivery rate
was 4%. The same preterm delivery rate of 4% was
observed in the larger study group of 386 patients.
Duration of pregnancy at delivery, obstetrical com-
plications and placental inflammatory changes are
shown in Table I. The preterm delivery rate was
higher in the study group compared to the control
group, but the difference was not statistically sig-
nificant. There were no cases of very preterm birth at
gestational age B28 weeks. Antibiotic use during
pregnancy, labour or delivery was similar between
study patients and controls. Symptomatic patients
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with BV (25%) all received metronidazole (2 in the
study group and 2 in the control group). Clinical
signs of CA  maternal fever, maternal and fetal
tachycardia, maternal leukocytosis  were only pre-
sent in 1 case (2.2%) with placental histological
inflammation.
The inflammatory changes in the placenta in
relation to the genital infections found at the first
prenatal visit are shown in Table II. Inflammatory
changes in the placenta were more frequent in
women with genital tract colonisation with G.
vaginalis (p0.013), S. aureus (p0.04) or the
presence of AV (p0.023) at first prenatal visit, as
well as in women having clinical BV at that time (p
0.031).
The role of genital mycoplasma was analysed
separately (Table II). Inflammatory changes in the
placenta were found more often in the group of
patients with RTI, but the rate of placenta infection
was not different whether mycoplasma colonisation
was present (34.8%) or not (36.9%). Both M. hominis
and U. urealyticum did not increase the risk for
intrauterine infection, unless when concurring with
other RTI or abnormal vaginal flora.
The presence of aerobic bacteria was clearly linked
with signs and symptoms of AV: abnormal vaginal
discharge, red inflamed vagina and increased leuko-
cytosis were all significantly more frequent in the
colonised than in the non-colonised group (Table
III).
The caesarean delivery rate in the whole group of
patients was 10.6% (16/151). There were 7 cases of
elective caesarean section  in these cases no
histological placental inflammation was detected.
On looking at different sites of placenta involved in
inflammation we recognised 33 cases of parietal CA
(71.7%), 25 cases of placental CA (54.3%), 15 cases
of funisitis (32.6%) and 8 cases of subchorial
Table I. Pregnancy and delivery complications and histological placental inflammation.
Histological placental inflammation
(n46) n (%)
No histological placental inflammation
detected (n105) n (%) p Value
Premature delivery 4 (8.6) 2 (1.9) 0.08
PROM 13 (28.2) 23 (21.9) 0.51
Duration of ruptured membranes (h)
B12 39 (84.8) 101 (96.2) 0.62
12 7 (15.2) 4 (3.8) 0.04
Systemic antibacterial treatment during
pregnancy, labour or delivery
13 (28.3) 16 (15.2) 0.13
Table II. RTI, endogenous vaginal flora and placental histological inflammation.
Placental histological
inflammation (n46) n (%)
No placental histological
inflammation detected (n105) n (%) p Value
Aerobic microorganisms and microflora patterns
S. aureus 7 (15.2) 4 (3.8) 0.04
GDS 5 (10.9) 7 (6.7) 0.51
GBS 4 (8.7) 4 (3.8) 0.26
Clinical AV 9 (20) 6 (5.7) 0.023
Sexually transmitted microorganisms
T. vaginalis 1 (2.2) 1 (1.0) 0.52
C. trachomatis 3 (6.5) 2 (1.9) 0.17
Bacterial vaginosis associated organisms or clinical patterns
U. urealyticum 21 (45.7) 28 (26.6) 0.11
M. hominis 3 (6.5) 5 (4.8) 0.7
G. vaginalis 13 (28.3) 10 (9.5) 0.013
Clinical BV 8 (17.4) 5 (4.8) 0.031
Abnormal cervico-vaginal colonisation (any of the above)
Without mycoplasma$ 17 (36.9) 11 (10.5) 0.002
With mycoplasma 16 (34.8) 15 (14.3) 0.023
Normal cervico-vaginal flora (none of the above)
Without mycoplasma 6 (13.0) 60 (57.1) 0.0007
With mycoplasma 7 (15.2) 19 (18.1) 0.71
$‘Mycoplasma’ are U. urealyticum and/or M. hominis.
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intervillitis (17.4%). Parietal and placental CA was
associated with the presence of BV (7/13, 53.8%)
and BV-related G. vaginalis (10/23, 43.5%), but
funisitis was associated with the presence of GDS
(4/12, 33.3%) and AV (6/15, 40.0%).
Discussion
The preterm delivery rate among 151 study patients
was comparable to the preterm birth rate in Latvia
during the same time period (3.9% in 2002) (3).
Association between infection and spontaneous pre-
term labour is well established and thought to be
responsible for preterm births in up to 40% of cases
(8). One particular causative factor in the pathogen-
esis of preterm labor is ascending infection from the
cervix and vagina, resulting in intrauterine infection,
preterm premature rupture of membranes (PPROM)
and untractable labour. In most healthy women, a
long and closed cervix, thick cervical mucus, intact
fetal membranes, and a competent maternal immune
system act together to accomplish an effective barrier
against the intrauterine migration of normal and
pathogenic cervicovaginal flora. In some women,
regardless of these protective factors, microorganisms
can ascend in the uterine cavity and cause inflamma-
tion of the placenta, extraplacental membranes and
amniotic fluid. Once passed the cervical barrier,
infection may cause diminished placental function,
premature rupture of membranes (PROM), preterm
delivery and fetal infection, both via the direct impact
of infectious agents or via organ damage by release of
inflammatory cytokines (2).
However, organisms often reside in the human
fetal membranes without harming the pregnancy
(9,10), and in 96% of the cases with placentitis; no
clinical manifestation of infection was present in
another study (10). In our data, histological inflam-
mation of the placenta mainly occurred in women
without clinical signs of CA and correlated with
duration of ruptured membranes, a finding also
described by others (11).
Prenatal abnormal vaginal flora has long been
recognised as a major risk factor for intrauterine
infection (12). BV is characterised by abnormal
vaginal flora (lactobacillary Grade III), with an
overgrowth of anaerobic and facultative anaerobic
bacteria, such as G. vaginalis, Bacteroides spp.,
Peptostreptococci, Mobiluncus, U. urealyticum, M. ho-
minis and a decrease or lack of normal flora, e.g.
Lactobacillus spp. (6,13). BV is common in normal
pregnancy and has been studied as a risk factor for
subclinical intrauterine infection (14). The preva-
lence of BV in Latvia is as low as 5.6% in pregnant
women and 75% of all cases are asymptomatic (15).
Many authors consider abnormal flora and BV a risk
factor for preterm delivery (13,16,17); however,
most women with BV deliver at term. Other studies
demonstrate that in a low risk population, BV did
not increase preterm birth risk (18,19), and in a
large randomised, placebo, controlled trial, the
treatment with metronidazole of asymptomatic BV
in pregnant women did not reduce the risk of
preterm delivery or adverse perinatal outcomes
(20,21). However, some recent studies using clin-
damycin early in pregnancy (22) showed a convin-
cing reduction of preterm birth rate. The revised
Cochrane database revealed no evidence that treat-
ment with metronidazole reduces the risk of preterm
birth, and demonstrated that the only effect of
treatment with clindamycin was seen in women
with intermediate flora (14). Therefore, a broader
spectrum antibiotic other than metronidazole, which
acts not only against anaerobic bacteria, but is also
active against anaerobes, like clindamycin, is war-
ranted.
Our study confirms the association of BV,
G. vaginalis and Mycoplasma colonisation with
placental histological inflammation. In this small
study group, however, patients with BV and in-
flammatory changes in placenta were not found to
have increased rates of preterm birth or poor
perinatal outcome. There is probably a subgroup
of women with BV who are at particularly high risk
for preterm delivery, for instance those who have
vaginal colonisation with M. hominis (17). Unfortu-
nately, due to the small number of women with M.
hominis infection, it was not possible to properly
evaluate the role of this microorganism on the risk
of pregnancy complications in our study. The only
Table III. Inflammatory vaginitis in correlation to aerobic vaginal flora.
One or more aerobic bacteria
detected (n28) n (%)
No RTI or BV
detected (n66) n (%) p Value
Patient complains for abnormal vaginal discharge 15 (53.6) 16 (24.2) 0.058
Red inflammation with mucous membrane lesions of vagina
and cervix
18 (64.3) 7 (10.6) 0.0001
Abnormal yellow vaginal discharge 16 (57.1) 4 (6.1) 0.00003
Presence of 10 leucocytes in high power field 21 (75.0) 23 (34.8) 0.04
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indications for systemic antibacterial treatment
during pregnancy for our study patients were
urinary tract infections, and treatment consisted of
penicillin, but never clindamycin.
In Latvian low risk pregnant women, M. hominis
and U. urealyticum are present in the vaginal tract in
1.5 and 28%, respectively (15). Mycoplasmata are
potentially pathogenic microorganisms, responsible
for an increased risk in preterm birth, PROM, CA
and neonatal infection (23). Whether mycoplas-
mata are a co-factor of genital infections or have a
crucial role in pathology is a matter of debate. We
compared the correlation of placental histological
inflammation in 3 patient groups: no mycoplasmata
found, only M. hominis and/or U. urealyticum were
present, or mycoplasmata in combination with
another RTI and/or abnormal endogenous vaginal
flora. We found no excess risk due to mycoplasma
as a single pathogen, but if combined with RTI,
their presence was associated with histological
placental inflammation. This confirms the hypoth-
esis that genital tract colonisation of mycoplasmata
has to be considered only as a potential marker for
an increased risk of infection-related pregnancy
complications, rather than a direct cause of intrau-
terine infection and preterm delivery. In this series,
BV increased the risk for histological placental
inflammation regardless of the presence of myco-
plasmata.
Colonisation with GBS, S. aureus or GDS was
twice as frequent in parturients with placental
inflammation compared to controls. GBS and other
aerobic bacteria are, in some symptomatic women,
involved in vaginitis with microscopic evidence of
vaginal inflammation (24). The clinical and micro-
scopic characteristics of AV differ from BV (7).
Donders et al. found dramatic concentrations of
pro-inflammatory cytokines, such as interleukin
1 (IL-1) and IL-6, in patients with AV and postu-
lated that AV, when occurring during pregnancy,
could be responsible for ascending intrauterine
infection and preterm birth (7). The data of our
study show that AV posed almost a 4-fold increased
risk for inflammatory changes in the placenta, and in
40% of all AV cases funisitis was presented. Severe
fetal placental lesions, such as funisitis, correlate
highly with neurological impairment and cerebral
palsy (25,26).
We conclude that inflammatory changes in the
placenta were associated with genital tract colonisa-
tion with specific bacteria, such as S. aureus and
G. vaginalis, as well as with AV and BV in early
gestation. Mycoplasmas may increase the risk of
placental inflammation if found in combination
with other RTIs or abnormal endogenous vaginal
flora.
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